πŸ‡ΊπŸ‡Έ FDA
Patent

US 10526604

Modulation of nuclear-retained RNA

granted A61PA61P15/00A61P21/00

Quick answer

US patent 10526604 (Modulation of nuclear-retained RNA) held by Ionis Pharmaceuticals, Inc. expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P15/00, A61P21/00, A61P21/04, A61P25/14